ImmuCell (NASDAQ:ICCC) Issues Quarterly Earnings Results

ImmuCell (NASDAQ:ICCC) released its earnings results on Thursday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $5.51 million for the quarter. ImmuCell had a return on equity of 6.25% and a net margin of 6.23%.

ImmuCell Price Performance

ICCC stock traded down $0.65 on Friday, reaching $5.40. 50,297 shares of the company’s stock were exchanged, compared to its average volume of 18,858. The stock has a fifty day moving average of $6.19 and a 200-day moving average of $6.23. The firm has a market cap of $48.85 million, a PE ratio of 28.42 and a beta of 0.29. The company has a quick ratio of 1.99, a current ratio of 3.85 and a debt-to-equity ratio of 0.28. ImmuCell has a twelve month low of $3.40 and a twelve month high of $7.60.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of ImmuCell in a research note on Thursday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Investors Weigh In On ImmuCell

An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC boosted its holdings in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 71,852 shares of the biotechnology company’s stock after acquiring an additional 2,907 shares during the period. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.